Arteriosclerosis obliterans

Summary

Arteriosclerosis obliterans (MONDO:0006659) is a disease and 10 clinical trials. Top therapeutic interventions include cilostazol, alprostadil, and probucol. A subtype of coronary atherosclerosis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 10

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	arteriosclerosis obliterans
Mondo ID	MONDO:0006659
EFO	EFO:1000820
MeSH	D001162
DOID	DOID:5160
SNOMED CT	361133006
UMLS	C0003851
MedGen	13915
MedDRA	10065418
Is cancer (heuristic)	no

Also known as: arteriosclerosis obliterans (disorder) [ambiguous]

Disease family

This is a subtype of coronary atherosclerosis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › vascular disorder › arterial disorder › coronary artery disorder › coronary atherosclerosis › arteriosclerosis obliterans

Related subtypes (1): arteriolosclerosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Alprostadil.

Clinical trials & evidence

Clinical trials

Clinical trials: 10.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	6
PHASE4	2
PHASE1/PHASE2	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00823849	PHASE4	COMPLETED	Study of Cilostazol and Probucol to Assess Their Effects on Atherosclerosis Related Biomarker
NCT00912756	PHASE4	UNKNOWN	Sufficient Treatment of Peripheral Intervention by Cilostazol
NCT02864654	PHASE1/PHASE2	UNKNOWN	Effectiveness and Safety of Adipose-Derived Regenerative Cells for the Treatment of Critical Lower Limb Ischemia
NCT02877173	PHASE2	UNKNOWN	A Safety/Efficacy Study of Alprostadil Liposomes for Injection to Treat Lower Extremity Arteriosclerosis Obliterans
NCT06485622	Not specified	RECRUITING	Outcome and Improvement of Different Treatment in Arteriosclerosis Obliterans
NCT07023965	Not specified	ENROLLING_BY_INVITATION	Follow-up Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-L)
NCT00145262	Not specified	UNKNOWN	TACT-NAGOYA: Therapeutic Angiogenesis Using Cell Transplantation
NCT00712946	Not specified	COMPLETED	Preoperative Heart Rate Variability and Baroreflex Sensitivity in ASO Patients During Various Sleep Stages
NCT01518205	Not specified	COMPLETED	HELP-Apheresis in Diabetic Ischemic Foot Treatment (H.A.D.I.F)
NCT02431234	Not specified	UNKNOWN	Arterial Calcification in the Diabetes

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CILOSTAZOL	4	2
ALPROSTADIL	4	1
PROBUCOL	4	1
CHEMBL443232	0	1